GB2551945B - Novel GLP-1 receptor agonist peptides - Google Patents

Novel GLP-1 receptor agonist peptides Download PDF

Info

Publication number
GB2551945B
GB2551945B GB1522431.4A GB201522431A GB2551945B GB 2551945 B GB2551945 B GB 2551945B GB 201522431 A GB201522431 A GB 201522431A GB 2551945 B GB2551945 B GB 2551945B
Authority
GB
United Kingdom
Prior art keywords
receptor agonist
agonist peptides
novel glp
glp
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1522431.4A
Other versions
GB2551945A (en
GB201522431D0 (en
Inventor
Andrews Steve
Stuart Congreve Miles
Bortolato Andrea
Stephen Mason Jonathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heptares Therapeutics Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GB1522431.4A priority Critical patent/GB2551945B/en
Publication of GB201522431D0 publication Critical patent/GB201522431D0/en
Publication of GB2551945A publication Critical patent/GB2551945A/en
Application granted granted Critical
Publication of GB2551945B publication Critical patent/GB2551945B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
GB1522431.4A 2015-12-18 2015-12-18 Novel GLP-1 receptor agonist peptides Active GB2551945B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1522431.4A GB2551945B (en) 2015-12-18 2015-12-18 Novel GLP-1 receptor agonist peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1522431.4A GB2551945B (en) 2015-12-18 2015-12-18 Novel GLP-1 receptor agonist peptides

Publications (3)

Publication Number Publication Date
GB201522431D0 GB201522431D0 (en) 2016-02-03
GB2551945A GB2551945A (en) 2018-01-10
GB2551945B true GB2551945B (en) 2021-09-08

Family

ID=55311262

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1522431.4A Active GB2551945B (en) 2015-12-18 2015-12-18 Novel GLP-1 receptor agonist peptides

Country Status (1)

Country Link
GB (1) GB2551945B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210008834A (en) * 2018-03-23 2021-01-25 카모트 테라퓨틱스, 인크. Modulators of G-protein coupled receptors
US11174235B2 (en) * 2018-06-14 2021-11-16 Championx Usa Inc. Carboxy alkyl-ester anti-agglomerants for the control of natural gas hydrates
CN115666623A (en) * 2020-03-16 2023-01-31 赫普泰雅治疗有限公司 Oral GLP receptor agonists
GB202003762D0 (en) * 2020-03-16 2020-04-29 Heptares Therapeutics Ltd GLP receptor agonists
CN111777521A (en) * 2020-07-22 2020-10-16 苏州爱玛特生物科技有限公司 Synthesis method of multi-configuration long-chain phenyl amino acid compound
EP4210767A1 (en) * 2020-09-14 2023-07-19 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
GB202016149D0 (en) * 2020-10-12 2020-11-25 Heptares Therapeutics Ltd Cyclic apelin receptor agonists
GB202016152D0 (en) * 2020-10-12 2020-11-25 Heptares Therapeutics Ltd Linear Apelin Receptor Agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US20110166321A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US20110166321A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives

Also Published As

Publication number Publication date
GB2551945A (en) 2018-01-10
GB201522431D0 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
IL267288B (en) Glp-1 receptor agonists and uses thereof
ZA201804997B (en) Triple glucagon/glp-1/gip receptor agonist
DK3445788T3 (en) Novel bispecific polypeptides against cd137
ZA201802371B (en) Glucagon receptor agonists
IL255767A (en) Novel polypeptides
IL247769A0 (en) Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4
IL252257A0 (en) Insulin receptor partial agonists
GB201514875D0 (en) Receptor
IL248013A0 (en) Dual glp-1/glucagon receptor agonists derived from exendin-4
HK1252163A1 (en) Receptor
GB2551945B (en) Novel GLP-1 receptor agonist peptides
ZA201700342B (en) Novel glp-1 receptor modulators
IL259793A (en) Slc45a2 peptides for immunotherapy
GB201702617D0 (en) Receptor
GB201506316D0 (en) Novel peptide
IL252565A0 (en) Novel glp-1 receptor modulators
EP3329922A4 (en) Glp-1 secretagogue
PL3247719T3 (en) Met receptor agonist proteins
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB201515245D0 (en) Novel polypeptides
GB201506360D0 (en) Novel peptide